Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate

Leukemia

Volumn 18, Issue 10, 2004, Pages 1656-1661

  Boissel, N ^a   Rousselot, P ^b   Raffoux, E ^b   Cayuela, J M ^c   Maarek, O ^c   Charron, D ^a   Degos, L ^b   Dombret, H ^b   Toubert, A ^a   Rea, Delphine ^a,b  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c Laboratoire Central d'Hematologie   (France)

Author keywords

Blood DC; CML; Imatinib; VEGF

Indexed keywords

HYDROXYUREA; IMATINIB; NEUROPILIN 1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INTERACTION; CELL POLARITY; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DRUG MONITORING; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; MALE; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

EID: 20844437248     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403474     Document Type: Article

References (29)

1. Baccarani M, Russo D, Rosti G, Martinelli G. Interferon-alpha for chronic myeloid leukemia. Sem Hematol 2003; 40: 22-33.
2. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Sem Hematol 2003; 40: 59-71.
3. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6 1018-1023.
4. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259-264.
5. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165: 6037-6046.
6. Dzionek A, Inagaki Y, Okawa K, Nagafune J, Rock J, Sohma Y et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002; 63: 1133-1148.
7. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGF-R2 and neuropilin-1 that enhances VEGF165-receptor binding. J Cell Biochem 2002; 85: 357-368.
8. Tordjman R, Lepelletier Y, Lemarchandel V, Cambot M, Gaulard P, Hermine O et al. A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat Immunol 2002; 3: 477-482.
9. Vicari AP, Caux C, Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002; 12: 33-42.
10. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A et al. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood 2002; 99: 2265-2267.
11. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1267.
12. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92 4150-4166.
13. Legros L, Bourcier C, Jacquel A, Mahon FX, Cassuto JP, Auberger P et al. Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma level in patients with chronic myeloid leukemia. Blood 2004; 104: 495-501.
14. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL et al. Plasmacytoid dendritic cells prime IFN-g-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33: 1052-1062.
15. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B et al. Dendritic cells are functionally defective in multiple myeloma. Blood 2002; 100: 230-237.
16. Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballeri XN et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 2001; 98 3750-3756.
17. Wysocka M, Zaki MH, French LE, Chehimi J, Shapiro M, Everetts SE et al. Sézary syndrome patients demonstrate a defect in dendritic cell populations: effect of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002; 100: 3287-3294.
18. Bellamy W, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
19. Gabrilovitch D, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999; 5: 2963-2970.
20. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hematopoietic progenitor cells. J Immunol 1998; 160: 1224-1232.
21. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001; 20: 8334-8341.
22. + stem cells into predendritic (pre-DC)2 but not into pre-DC1: evidence for a lymphoid origin of pre-DC2. J Exp Med 2000; 192: 1775-1783.
23. Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001; 276: 28570-28577.
24. Reuben JM, Lee B-N, Johnson H, Fritsche H, Kantarjian HM, Talpaz M. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin Cancer Res 2000; 6: 1671-1677.
25. Young JW, Szabolcs P, Moore MA. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1995; 182: 1111-1119.
26. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buhring HJ et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004; 103: 523-529.
27. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538-544.
28. Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 2004; 103: 1966-1967.
29. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. International Randomised Study of interferon vs STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.